| |
|
Headlines:
|
 |
Back
to index
Vepside (VP-16) single agent
Abstract: Effect of low-dose oral etoposide on serum CA-125 in patients
with advanced epithelial ovarian cancer
The effect of oral etoposide on CA-125 serum levels was evaluated in
17 patients with epithelial ovarian cancer and progressive disease during,
or relapsing after, prior chemotherapy. Only three patients had measurable
lesions at extraperitoneal sites. Five had no measurable lesions. The oral
etoposide dose was 50 mg b.d. for 7 days every 3 weeks, escalating to 10
or 14 days and continued until clinical progression. CA-125 after 4 courses
was compared to baseline (CA-125 ratio). The rate of change of CA-125 (s,
slope of the exponential regression curve) during the first 4 courses was
compared to s over a similar period before treatment. One patient had a
clinical partial response. Two other patients had a biochemical response
(CA-125 ratio <0.5). Although the biochemical response rate was modest (12.5%),
a decrease of s was observed in 14/16 patients (P = 0.02). The mean change
of s represented an increase of mean doubling time from 52 to 693 days.
No patients were withdrawn because of toxicity. General malaise, nausea,
diarrhea, and anemia were the most important side effects. At the given
dose schedule, oral etoposide shows activity in advanced ovarian cancer
if the rate of change of CA-125 is used as a measure of activity.
References
de Jong RS, Hofstra LS, Willemse PH, de Bruijn HW, de Vries EG, Boonstra
H, Mulder NH. Effect of low-dose oral etoposide on serum CA-125 in patients
with advanced epithelial ovarian cancer. Gynecol Oncol 1997; 66:197 - 201.
|
|
|
|
Are you a doctor or a nurse?
Do you want to join the Doctors Lounge online medical community?
Participate in editorial activities (publish, peer review, edit) and
give a helping hand to the largest online community of patients.
Click on the link below to see the requirements:
Doctors Lounge Membership
Application |
|
| Regimen |
|
VP - 16....... 50 mg PO BID
days 1 - 7
FREQUENCY every 21 days |
|
|
| |
|
|
| |
Summary |
|
| |
Overall Response
Rate |
|
| |
Progression
Free Survival |
|
| |
Overall Survival |
|
| |
Toxicity |
|
| |
|
|
|
|
send
to a friend
printer
friendly version
